Syros Pharmaceuticals Garners $40,000,000 New Financing

  • Feed Type
  • Date
    1/13/2016
  • Company Name
    Syros Pharmaceuticals
  • Mailing Address
    620 Memorial Drive Cambridge, MA 02139 USA
  • Company Description
    Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities.
  • Website
    http://www.syros.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from the financing will be used to advance the Company’s pipeline of gene control medicines, including a Phase 2 study of its lead program, SY-1425, which is expected to begin in the first half of 2016 in a genomically defined subset of patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). The funds will also be used to further develop the Company’s proprietary gene control platform with the aim of uncovering novel drug targets and biomarkers and developing medicines to treat cancer and other serious diseases.
  • M&A Terms
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Casdin Capital
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    WuXi PharmaTech
  • Venture Investor
    Polaris Partners
  • Venture Investor
    Redmile Group
  • Venture Investor
    Aisling Capital
  • Venture Investor
    Alexandria Venture Investments